Total Payments
$360,300
2024 Payments
$176,657
Companies
46
Transactions
918
Medicare Patients
2,648
Medicare Billing
$291,904
Payment Breakdown by Category
Other$254,539 (70.6%)
Travel$43,967 (12.2%)
Consulting$36,555 (10.1%)
Food & Beverage$24,935 (6.9%)
Education$189.24 (0.1%)
Research$114.66 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $254,540 | 75 | 70.6% |
| Travel and Lodging | $43,967 | 85 | 12.2% |
| Consulting Fee | $36,555 | 19 | 10.1% |
| Food and Beverage | $24,935 | 725 | 6.9% |
| Education | $189.24 | 9 | 0.1% |
| Unspecified | $114.66 | 5 | 0.0% |
Payments by Type
General
$360,185
913 transactions
Research
$114.66
1 transactions
Ownership
$0
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $150,024 | 324 | $0 (2024) |
| Janssen Biotech, Inc. | $72,743 | 88 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $45,176 | 36 | $0 (2024) |
| PFIZER INC. | $35,228 | 65 | $0 (2024) |
| Lilly USA, LLC | $19,194 | 28 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $11,841 | 32 | $0 (2024) |
| Janssen Global Services, LLC | $6,710 | 16 | $0 (2023) |
| Celgene Corporation | $6,174 | 88 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $4,359 | 34 | $0 (2024) |
| GastroGPO, LLC | $2,276 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $176,657 | 300 | Janssen Biotech, Inc. ($68,274) |
| 2023 | $102,018 | 245 | AbbVie Inc. ($70,457) |
| 2022 | $74,812 | 191 | ABBVIE INC. ($38,288) |
| 2021 | $3,994 | 84 | AbbVie Inc. ($2,815) |
| 2020 | $701.84 | 34 | AbbVie Inc. ($248.98) |
| 2019 | $1,289 | 49 | PFIZER INC. ($487.75) |
| 2018 | $416.30 | 11 | Janssen Scientific Affairs, LLC ($235.53) |
| 2017 | $411.08 | 4 | Synergy Pharmaceuticals Inc ($125.00) |
All Payment Transactions
918 individual payment records from CMS Open Payments — Page 1 of 37
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $23.05 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $13.00 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $0.26 | General |
| Category: Immunology | ||||||
| 12/12/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $11.87 | General |
| Category: VIROLOGY | ||||||
| 12/10/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $15.12 | General |
| Category: Gastroenterology | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,865.00 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $942.24 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $126.21 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $16.52 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $15.56 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/04/2024 | PFIZER INC. | VELSIPITY (Drug) | Food and Beverage | In-kind items and services | $12.59 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 12/03/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $25.16 | General |
| Category: IMMUNOLOGY | ||||||
| 12/02/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $2.44 | General |
| Category: Gastroenterology | ||||||
| 12/02/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $0.48 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/26/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $12.11 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/25/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $29.90 | General |
| Category: LIVER DISEASE | ||||||
| 11/19/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $21.86 | General |
| Category: IMMUNOLOGY | ||||||
| 11/16/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,390.00 | General |
| Category: Immunology | ||||||
| 11/15/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $23.83 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $16.26 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/14/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $12.99 | General |
| Category: Immunology | ||||||
| 11/13/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $12.01 | General |
| Category: Gastroenterology | ||||||
| 11/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $19.40 | General |
| Category: Gastroenterology | ||||||
| 11/08/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,875.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/08/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $35.17 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS | Eli Lilly and Company | $114.66 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 649 | 691 | $427,344 | $77,909 |
| 2022 | 17 | 760 | 843 | $416,217 | $82,561 |
| 2021 | 12 | 800 | 884 | $395,305 | $85,149 |
| 2020 | 11 | 439 | 517 | $208,929 | $46,285 |
Total Patients
2,648
Total Services
2,935
Medicare Billing
$291,904
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 128 | 128 | $149,888 | $24,422 | 16.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 85 | 105 | $24,675 | $9,869 | 40.0% |
| 91110 | Imaging of digestive tract done from the inside of the digestive tract | Office | 2023 | 16 | 16 | $35,200 | $9,719 | 27.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 101 | 101 | $89,183 | $8,156 | 9.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 90 | 112 | $17,920 | $7,049 | 39.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 89 | 89 | $52,688 | $5,393 | 10.2% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 21 | 21 | $16,863 | $3,764 | 22.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 39 | 39 | $9,165 | $2,762 | 30.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 25 | 25 | $9,125 | $2,700 | 29.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 19 | 19 | $5,890 | $1,941 | 32.9% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2023 | 13 | 13 | $9,022 | $1,170 | 13.0% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 12 | 12 | $6,900 | $764.20 | 11.1% |
| 91200 | Measurement of liver stiffness | Office | 2023 | 11 | 11 | $825.00 | $199.92 | 24.2% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 102 | 102 | $119,442 | $19,733 | 16.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 91 | 126 | $29,610 | $12,565 | 42.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 138 | 171 | $27,360 | $10,971 | 40.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 97 | 97 | $85,651 | $8,452 | 9.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 86 | 88 | $52,096 | $6,360 | 12.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 66 | 66 | $15,510 | $5,144 | 33.2% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 26 | 26 | $20,878 | $4,665 | 22.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 23 | 23 | $8,395 | $3,043 | 36.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 18 | 18 | $8,190 | $2,778 | 33.9% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 13 | 13 | $10,634 | $2,385 | 22.4% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 18 | 19 | $10,925 | $1,282 | 11.7% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2022 | 13 | 14 | $9,716 | $1,195 | 12.3% |
About Dr. Harry Thomas, MD
Dr. Harry Thomas, MD is a Gastroenterology healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/10/2008. The National Provider Identifier (NPI) number assigned to this provider is 1104086628.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Harry Thomas, MD has received a total of $360,300 in payments from pharmaceutical and medical device companies, with $176,657 received in 2024. These payments were reported across 918 transactions from 46 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($254,540).
As a Medicare-enrolled provider, Thomas has provided services to 2,648 Medicare beneficiaries, totaling 2,935 services with total Medicare billing of $291,904. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Austin, TX
- Active Since 06/10/2008
- Last Updated 08/16/2023
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1104086628
Products in Payments
- SKYRIZI (Biological) $73,373
- RINVOQ (Biological) $73,039
- TREMFYA (Drug) $62,481
- ZEPOSIA (Drug) $40,485
- VELSIPITY (Drug) $34,115
- OMVOH (Drug) $16,541
- STELARA (Biological) $14,510
- ENTYVIO (Biological) $11,614
- SIMPONI (Biological) $6,710
- DUPIXENT (Biological) $1,718
- XIFAXAN (Drug) $1,125
- XELJANZ (Drug) $695.35
- MAVYRET (Drug) $569.91
- HUMIRA (Biological) $555.99
- Linzess (Drug) $230.06
- VIBERZI (Drug) $212.62
- TRULANCE (Drug) $203.89
- CREON (Drug) $195.19
- SIGNIA (Device) $157.58
- Humira (Biological) $139.72
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Austin
Dr. Harish Gagneja, Md, MD
Gastroenterology — Payments: $760,415
Gastroenterology $760,415
Dr. Pradeep Kumar, M.d, M.D
Gastroenterology — Payments: $94,961
Gastroenterology $94,961
Dr. Jianhua Tau, M.d, M.D
Gastroenterology — Payments: $90,140
Gastroenterology $90,140
Dr. Scott Becker, M.d, M.D
Gastroenterology — Payments: $46,704
Gastroenterology $46,704
Binh Pham, M.d, M.D
Gastroenterology — Payments: $37,217
Gastroenterology $37,217
Dr. Benjamin Havemann, M.d, M.D
Gastroenterology — Payments: $36,638
Gastroenterology $36,638